# Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer

> **NCT07333937** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Brest Cancer

## Interventions

- **DRUG:** Neratinib Combined with Fulvestrant and Eribulin

## Key facts

- **NCT ID:** NCT07333937
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-11-20
- **Final completion:** 2028-11-20
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07333937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07333937, "Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07333937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*